EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Biomarker testing in advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2 negative breast cancer: expert recommendations

Tomás Reinert iD, Ahmed S Alshehri, Amr Shafik, Ching-Hung Lin, Gonzalo Gomez Abuin, Gyungyub Gong, Kyung Hae Jung iD, Mora Amat, Nirmala Pathmanathan, Samuel G W Ow, Samuel Rivera-Rivera, Shyam Aggarwal und 2 weitere

Therapeutic Advances in Medical Oncology · 2026-08 · 18

DOI: 10.1177/17588359261472325 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 16.08.2026. Verfasst von Tomás Reinert und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Nora Teixeira/Santa Casa de Porto Alegre, Porto Alegre, Brazil. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca international.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biomarker testing is central to precision oncology, enabling effective use of targeted therapies in hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC). Recommendations for current and future biomarker testing and diagnostic workflows were developed using a three-step approach: pre-meeting survey, descriptive analysis, and steering committee discussion. A panel of 14 experts from Latin America, Asia Pacific, the Middle East, and Africa developed recommendations using an expert opinion-based approach without a formal consensus methodology. Recommendations with >90% agreement were considered panel recommendations. Some recommendations are expert-driven and not yet standard-of-care. High agreement was observed for biomarker testing at diagnosis for estrogen receptor (ER), progesterone receptor (PR), HER2, and BReast CAncer gene (BRCA)1/2. For endocrine-resistant patients, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) testing is recommended at diagnosis; otherwise, during or after first-line treatment. AKT serine/threonine kinase 1 (AKT1) and phosphatase and tensin homolog (PTEN) testing can occur either during first-line treatment or at progression, while estrogen receptor 1 (ESR1) testing is advised at progression. Tumor tissue (preferably from a re-biopsy) is the preferred sample for PIK3CA, AKT1, and PTEN testing; if unavailable, primary tissue or circulating tumor DNA (ctDNA) may be considered. Blood is recommended for germline BRCA1/2 or PALB2 testing, while ctDNA is preferred for ESR1 detection. Next-generation sequencing (NGS) is the preferred method for most biomarkers, with polymerase chain reaction as an alternative where NGS is unavailable; PTEN may also be assessed using immunohistochemistry. Above 90% of experts proposed future biomarker testing at diagnosis for ER, PR, HER2, germline BRCA1/2, PALB2, PIK3CA, AKT1, PTEN, mismatch repair, microsatellite instability, tumor mutational burden, and neurotrophic tyrosine receptor kinase in all patients with HR+, HER2-negative mBC. This article offers a practical guide for biomarker testing in HR+, HER2-negative mBC.

Schlagwörter

Stichwörter der Autor:innen

ESR1HER2-negativePIK3CAbiomarkersbreast cancermutationsnext-generation sequencingpolymerase chain reactionprecision medicinetumor tissue

Autor:innen und Institutionen

  • Hospital Nora Teixeira/Santa Casa de Porto Alegre, Porto Alegre, Brazil.
  • Department of Medical Oncology, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
  • Internal Medicine and Medical Oncology, Princess Noorah Oncology Center, Jeddah, Saudi Arabia.
  • King Abdulaziz Medical City, Jeddah, Saudi Arabia.
  • Department of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
  • Department of Medical Oncology, and Quality Control and Infection Control Center, National Taiwan University, Cancer Center Branch, Taipei City, Taiwan.

ORCID-Profile: Tomás Reinert, Kyung Hae Jung

Förderung

  • AstraZeneca international

Zitieren

APA

Reinert, T., Alshehri, A. S., Shafik, A., Lin, C. H., Gomez Abuin, G., Gong, G., Jung, K. H., Amat, M., Pathmanathan, N., Ow, S. G. W., Rivera-Rivera, S., Aggarwal, S., Luen, S. J., & Yong Tay, T. K. (2026). Biomarker testing in advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2 negative breast cancer: expert recommendations. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261472325

Vancouver

Reinert T, Alshehri AS, Shafik A, Lin CH, Gomez Abuin G, Gong G, et al. Biomarker testing in advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2 negative breast cancer: expert recommendations. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261472325

BibTeX
@article{Reinert2026,
  author = {Reinert, Tomás and Alshehri, Ahmed S and Shafik, Amr and Lin, Ching-Hung and Gomez Abuin, Gonzalo and Gong, Gyungyub and Jung, Kyung Hae and Amat, Mora and Pathmanathan, Nirmala and Ow, Samuel G W and Rivera-Rivera, Samuel and Aggarwal, Shyam and Luen, Stephen J and Yong Tay, Timothy Kwang},
  title = {Biomarker testing in advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2 negative breast cancer: expert recommendations},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261472325}
}
Kostenlos starten →